The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent Inhalation Solution? Atrovent Inhalation ...
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that ... · ACCESS Newswire · Amphastar Pharmaceuticals, Inc. Amphastar ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent UDV? Atrovent Unit Dose Vial (UDV) contains ...
Ipratropium bromide is used in bronchial asthma and in chronic obstructive pulmonary disease (COPD- a group of diseases that affect the lungs and airways). Ipratropium provides symptomatic relief from ...
Learn everything you need to know about Ipratropium Bromide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
Lupin is releasing Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, which are the generic of Boehringer Ingelheim’s Atrovent Nasal Spray, 0.03% and 0.06%. Ipratropium Bromide Nasal ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution(0.03%) under abbreviated new drug application(ANDA). The approved drug is a generic of Atrovent Nasal ...
We used national Veteran's Health Administration health-care databases for this analysis, including inpatient and outpatient data, pharmacy data, and vital status information. The cohort in this ...
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results